pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

India streamlines regulations for outsourced medical device sterilization

Aug 31, 2026·read at raps ↗RegulatoryPositive

The Indian government announced a simplification of the regulatory framework governing outsourced sterilization of medical devices. The move is part of a broader effort to make it easier for businesses to operate in the sector. By reducing procedural hurdles, the change is expected to lower costs and speed up the availability of sterilized devices.

Industry observers see the update as a positive step toward supporting growth and innovation in India's medical device market.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Asia-Pacific Roundup: India simplifies regulatory framework for outsourced sterilization of medical devices”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoRecon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88Braps
  • 1d agoIndustry, patient groups seek changes to FDA’s revised master protocols guidanceraps
  • 1d agoExperts propose suggestions to improve transparency of FDA complete response lettersraps
  • 4d agoFDA issues untitled letter to Alar for false advertising of investigational drugraps
  • 4d agoThis Week at FDA: HHS considering new FDA posts, FDA approves slew of firsts, and moreraps